http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SI-2004155-T1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b74452a889073845b47a40e23c273814
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2835
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D279-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-003
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
filingDate 2007-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5674d0242b5fadc3dc4e3aedb8daa6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d5e1ba9cd30a64b465e9dc6bb7097c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08039f8d258f7f193d7c45129f3492f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f90915c5c3705534bcf159cefdda5e3
publicationDate 2018-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber SI-2004155-T1
titleOfInvention Protein aggregation inhibitors
abstract This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of the following formula: wherein: each of R1 and R9 is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methylthioninium chloride, MTC).
priorityDate 2006-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6099
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419598433
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457444288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448333909
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6129
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID681
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13907918
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419548905
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457574860
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456171974

Total number of triples: 38.